金币
UID24640
帖子
主题
积分18447
注册时间2012-3-30
最后登录1970-1-1
听众
性别保密
|
欢迎您注册蒲公英
您需要 登录 才可以下载或查看,没有帐号?立即注册
x
本帖最后由 kslam 于 2016-8-24 11:03 编辑
FDA在2016年8月16日发警告信给湖州欧宝卫生用品有限公司。之前, FDA在2016年8月5日发进口禁令 66-40。
违规条款:
1. Your firm does not have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)).
公司对各批次药品放行之前没有进行适当的化验室检验,确定药品符合最终质量标准,包括每种活性成分的鉴别和剂量(21 CFR 211.165(a))。
2. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of such stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).
你们公司未建立和遵守书面的检验程序,用以评估药品的稳定性,并使用此类稳定性检测结果来决定适当的存贮条件和有效期(21 CFR 211.166(a))。
3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).
公司没有建立书面生产程序和工艺控制程序,包括验证方案和报告,用以保证你们公司的药品具有其理应具备或声称具备的剂量、质量和纯度(21 CFR 211.100(a))。
4. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).
公司未能为生产、加工、包装或存贮药品的设备建立和遵守书面的清洁和维护程序(21 CFR 211.67(b))。
5. Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.188).
公司未能建立每批有关生产和控制的完整资料。(21 CFR 211.188).
|
|